Literature DB >> 7647079

A comparison of placebo responders and nonresponders in subgroups of depressive disorder.

R J Bialik1, A V Ravindran, D Bakish, Y D Lapierre.   

Abstract

The objective of this study was to determine if the placebo treatment response varied in subgroups of depressed patients (single episode, recurrent, and double depression). Data from placebo-treated patients from seven placebo-controlled clinical trials were pooled and analyzed retrospectively. The placebo response rate was highest for females with a single episode of depression (66.7%) and lowest for females with recurrent depressive episodes (13.3%). Among patients experiencing their first episode, placebo responders had lower Hamilton Rating Scale for Depression (HAMD) total scores at baseline and lower ratings of pschomotor retardation than nonresponders. For patients having a recurrence of an episode, placebo responders had lower baseline ratings of somatic anxiety. The major finding was that patients suffering from their first depressive episode differed from patients with recurrent depressive episodes in the rate of placebo response, effect of gender, and the clinical symptoms that were associated with a positive placebo response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647079      PMCID: PMC1188700     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  23 in total

1.  Impact of multiple comparisons in randomized clinical trials.

Authors:  D G Smith; J Clemens; W Crede; M Harvey; E J Gracely
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

2.  Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology.

Authors:  G L Klerman
Journal:  Psychopharmacol Bull       Date:  1986

3.  The placebo effect.

Authors:  N Svedmyr
Journal:  Scand J Rehabil Med       Date:  1979

4.  The efficacy of antidepressant drugs. A review of research (1958-1972).

Authors:  J B Morris; A T Beck
Journal:  Arch Gen Psychiatry       Date:  1974-05

5.  Placebo problems in psychotherapy research. Social-psychological alternatives to chemotherapy concepts.

Authors:  W Wilkins
Journal:  Am Psychol       Date:  1986-05

6.  Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

Authors:  M H Trivedi; H Rush
Journal:  Neuropsychopharmacology       Date:  1994-08       Impact factor: 7.853

7.  "Double depression": superimposition of acute depressive episodes on chronic depressive disorders.

Authors:  M B Keller; R W Shapiro
Journal:  Am J Psychiatry       Date:  1982-04       Impact factor: 18.112

8.  How much of the placebo 'effect' is really statistical regression?

Authors:  C J McDonald; S A Mazzuca; G P McCabe
Journal:  Stat Med       Date:  1983 Oct-Dec       Impact factor: 2.373

9.  Baseline characteristics of 10-day placebo washout responders in antidepressant trials.

Authors:  J G Rabkin; J W Stewart; P J McGrath; J S Markowitz; W Harrison; F M Quitkin
Journal:  Psychiatry Res       Date:  1987-05       Impact factor: 3.222

10.  Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness.

Authors:  J W Stewart; F M Quitkin; M R Liebowitz; P J McGrath; W M Harrison; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1983-02
View more
  10 in total

Review 1.  Design of clinical trials of antidepressants: should a placebo control arm be included?

Authors:  J Fritze; H J Möller
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues.

Authors:  James A Blumenthal; Andrew Sherwood; Sharon D Rogers; Michael A Babyak; P Murali Doraiswamy; Lana Watkins; Benson M Hoffman; Cara O'Connell; Julie J Johnson; Seema M Patidar; Robert Waugh; Alan Hinderliter
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

3.  From the Bench to the Trench: A Comparison of Sertraline Treatment of Major Depression in Clinical and Research Patient Samples.

Authors:  R Bruce Lydiard; Philip Perera; Evan Batzar; Cathryn M. Clary
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-10

Review 4.  Mechanisms of the placebo effect in pain and psychiatric disorders.

Authors:  R D Holmes; A K Tiwari; J L Kennedy
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

5.  Depression history, stress, and pain in rheumatoid arthritis patients.

Authors:  Alex J Zautra; Brendt P Parrish; Christina M Van Puymbroeck; Howard Tennen; Mary C Davis; John W Reich; Mike Irwin
Journal:  J Behav Med       Date:  2007-04-05

6.  Placebo response in depression.

Authors:  Shamsah B Sonawalla; Jerrold F Rosenbaum
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

7.  Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies.

Authors:  Florian Naudet; Anne Solène Maria; Bruno Falissard
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

8.  Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.

Authors:  E Harada; M Kato; S Fujikoshi; M M Wohlreich; L Berggren; H Tokuoka
Journal:  Int J Clin Pract       Date:  2015-05-16       Impact factor: 2.503

9.  Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan.

Authors:  Yoshinori Watanabe; Yuko Asami; Yoko Hirano; Kazuhiko Kuribayashi; Rio Itamura; Takayuki Imaeda
Journal:  Neuropsychiatr Dis Treat       Date:  2018-05-16       Impact factor: 2.570

Review 10.  What can clinicians do to improve outcomes across psychiatric treatments: a conceptual review of non-specific components.

Authors:  S Priebe; M Conneely; R McCabe; V Bird
Journal:  Epidemiol Psychiatr Sci       Date:  2019-08-15       Impact factor: 6.892

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.